Get started
Author

Gaetano Scifo

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
2018 · Vincenza Calvaruso, Giuseppe Cabibbo, et al. · Gastroenterology · 376
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
2019 · Giuseppe Cabibbo, Ciro Celsa, et al. · Journal of Hepatology · 210
Real-world experience with obeticholic acid in patients with primary biliary cholangitis
2021 · Daphne D’Amato, Antonio De Vincentis, et al. · JHEP Reports · 85
PDF
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience
2019 · Vincenza Calvaruso, Irene Cacciola, et al. · The American Journal of Gastroenterology · 47
Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
2022 · Antonio De Vincentis, Daphne D'Amato, et al. · Liver International · 30
PDF
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort
2021 · Vincenza Calvaruso, Salvatore Petta, et al. · Journal of Viral Hepatitis · 25
PDF
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy
2019 · Umberto Vespasiani-Gentilucci, Floriano Rosina, et al. · Scandinavian Journal of Gastroenterology · 14
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real‐life study
2016 · Adriano M. Pellicelli, Valeria Pace Palitti, et al. · Liver International · 13
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
2024 · Antonio De Vincentis, Javier Ampuero, et al. · Clinical Gastroenterology and Hepatology · 12
PDF
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
2019 · Adriano Pellicelli, Vincenzo Messina, et al. · Gut and Liver · 12
PDF
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience
2016 · Antonio Ascione, CLEO Study Group, et al. · World Journal of Hepatology · 9
Current practice of hepatitis C treatment in Southern Italy
2010 · Tommaso Stroffolini, Aldo Spadaro, et al. · Digestive and Liver Disease · 9
PDF
Factors Enhancing Treatment of Hepatitis C Virus–Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience
2021 · Luca Rinaldi, Vincenzo Messina, et al. · The American Journal of Gastroenterology · 5
Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study
2023 · F. Terracciani, A. De Vincentis, et al. · Digestive and Liver Disease · 4
Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
2020 · Rodolfo Sacco, Vincenzo Messina, et al. · Drugs in Context · 3
PDF
Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study
2023 · Francesca Terracciani, Antonio De Vincentis, et al. · Journal of Hepatology · 2
FRI-067-Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database
2019 · Umberto Vespasiani Gentilucci, Floriano Rosina, et al. · Journal of Hepatology · 1
Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)
2023 · Antonio De Vincentis, Francesca Terracciani, et al. · Journal of Hepatology
Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)
2023 · A. De Vincentis, F. Terracciani, et al. · Digestive and Liver Disease
Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort
2022 · F. Salomone, I. Cacciola, et al. · Digestive and Liver Disease
Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience
2020 · Vincenzo Messina, Vincenzo Iovinella, et al. · Journal of Hepatology
Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort
2020 · Irene Cacciola, Salvatore Petta, et al. · Journal of Hepatology
Works count: 22
Citation count: 857
H-index: 10
I10-index: 10
Year
Topic
Type